HC Wainwright Maintains Axogen Buy Rating, Raises Target to $56
HC Wainwright & Co. raised its price target from $53 to $56 while maintaining its Buy rating. The new target implies 13.7% upside from Axogen’s Oct. 28 close of $49.25.
HC Wainwright & Co. raised its price target from $53 to $56 while maintaining its Buy rating. The new target implies 13.7% upside from Axogen’s Oct. 28 close of $49.25.